fluzoparib+camrelizumab

DRUG2 trials

Sponsors

Tianjin Medical University Cancer Institute and Hospital, wang shusen

Conditions

Advanced HER2 Negative Breast CarcinomaAdvanced HER2 Negative Breast Carcinoma HRD+Breast CancerHRD+Breast Cancer

Phase 2

Fluzoparib in Combination With Chidamide or Camrelizumab for HRD Positive HER2 Negative Advanced Breast Cancer

Tianjin Medical University Cancer Institute and HospitalAdvanced HER2 Negative Breast Carcinoma, HRD+Breast Cancer

Start: 2021-02-08End: 2024-12-31Target: 40Updated: 2022-09-29

Fluzoparib in Combination With or Without Camrelizumab for Homologous Recombinant Deficiency (HRD) HER2 Negative Advanced Breast Cancer

SuspendedNCT05656131

wang shusenAdvanced HER2 Negative Breast Carcinoma HRD+Breast Cancer

Start: 2022-11-23End: 2027-12-31Target: 80Updated: 2026-03-17

Related Papers

PS5-06-19: Sacituzumab Govitecan Combined with Anti-angiogenic Therapy and Radiotherapy in a BRCA1-Mutated Triple-Negative Breast Cancer Patient with Multiple Recurrences: A Case Report

Clinical Cancer Research2026-02-17